🟢 SAB Biotherapeutics is trading 5.8% up in pre-market — reason remains unclear

SAB Biotherapeutics is trading at $2.74, up 5.79% in pre-market; the reason for the move remains unclear.

• No October 16 company-specific catalyst was identified.
• The latest releases listed by the company were an October 14 conference participation announcement and an October 13 FDA Fast Track designation for SAB-142; neither establishes a reason for the pre-market move.
• Broader market indicators provided were mixed and did not show a strong same-direction move to explain the gain.